The net payment for the acquisition will be approximately US$501 million, as this figure excludes LaNova’s estimated cash and bank deposits of around US$450 million.
Gavi’s broader goal of protecting 1.1 billion children by 2025 has already been surpassed, with 1.2 billion children protected since 2000.
This state-of-the-art facility focuses on the research, development, and manufacturing of semi-finished components used in bioresorbable medical devices.
Budenheim’s range of phosphate-based excipients stands out for its unique high bulk density, which enables companies to manufacture smaller tablets without compromising mechanical integrity.
This divestiture is part of BD’s five-year plan to sharpen its focus on core medical supplies and drug delivery technologies.
This decision took effect on July 11, 2025, and allows for a clean and structured exit from a legacy business segment, freeing up capital and management focus on antibiotic and insulin manufacturing
In a Complete Response Letter (CRL) sent to Ultragenyx, the FDA cited manufacturing-related concerns tied to facility processes and practices observed during inspections.
Novartis plans to introduce Coartem Baby primarily on a not-for-profit basis to improve access in malaria-endemic regions, reflecting its long-term commitment to fighting malaria.
Johnson & Johnson aims extend Akeega’s approval to include patients with metastatic hormone-sensitive prostate cancer (mHSPC) who have homologous recombination repair (HRR) gene alterations.